Jounce Therapeutics Inc (JNCE)

NASDAQ
1.880
0.000(0.00%)
  • Volume:
    0
  • Day's Range:
    1.880 - 1.930
  • 52 wk Range:
    0.577 - 5.370

JNCE Overview

Prev. Close
1.88
Day's Range
1.88-1.93
Revenue
82M
Open
1.92
52 wk Range
0.577-5.37
EPS
-0.985
Volume
0
Market Cap
98.96M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,161,967
P/E Ratio
-1.91
Beta
0.633
1-Year Change
-50.13%
Shares Outstanding
52,636,235
Next Earnings Date
-
What is your sentiment on Jounce Therapeutics?
or
Vote to see community's results!

Jounce Therapeutics Inc Company Profile

Jounce Therapeutics Inc Company Profile

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. As of May 3, 2023, Jounce Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Test Can Not SHORT 👉 Never Buy 👉 DELETE
    0
    • 🚀💰
      0
      • I was ready to dump this stock and was waiting for the 7.45 range so I can break even since May timeline...I never expected the good news today.. this will explode with big pharma investors...I was pleasantly surprised today with this news. this originally had a target price of 9.50 and it should be a good investment for 2021..so hold on for the ride! ..
        0
        • Worth 0.8B
          0
          • Gilead signs with Jnce and will pay $35m upfront in shares and later up to $685m royalties, great news for Jnce
            0
            • hello ! somebody have any new regarding JNCE, will it go up soon?
              0
              • target: $15
                0
                • Short this ?
                  1